Science & Evidence | EBCD Website

A Superior Mammogram with EBCD™

How EBCD™ Works¹

Radiologist Review with AI Aid:
A radiologist reviews the mammogram using an FDA-cleared AI software tool that aids in cancer detection by identifying lesions and calcifications.
AI Comparative Review:
The AI software output is compared to the initial assessment made by the radiologist.
Expert Second Review if Needed:
If the AI makes an alternate conclusion than the radiologist, a second expert radiologist reviews the exam.
Finalized Results:
The result is finalized by the radiologist after all steps are completed, delivering one confident report with 21% more cancers detected and potential for lower recall rates.²

	EBCD™	Typical AI Solutions
Cancer Detection Improvement	+21% Overall +21% real-world (23% in dense breasts); detects aggressive cancers equitably.³	+10-20% Overall +10-20% primarily in European studies (e.g., 29% for Transpara replacing a second reader); 5-30% variable by product, with limited or nonsignificant evidence of cancer detection rate increases in real-world US studies.⁴
Equity & Inclusivity	Equitable Across All No differences by race, ethnicity, or density; +20% in Black women; addresses disparities.⁵	Limited Equity Focus Benefits for dense breasts noted; sparse data on race/ethnicity equity, particularly from the US.⁶
Core Approach	AI + Expert Review Workflow Built-in specialist double-reading on all flagged cases.⁷	AI as Add-On Aid Single-reader with AI assistance; no routine second review.⁸
Recall Reduction	17% Fewer Recalls 17% decrease in recall rate at one practice in 4 months through EBCD™, reducing patient anxiety and unnecessary tests.⁹	Mixed Results Some reductions claimed; often neutral or increased recalls in studies.¹⁰
Real-World Evidence	579,583 Women Studied Massive real-world data in 5 practices across the U.S. (200+ sites) shows additional cancers found nationally.¹¹	Smaller Studies Studies on one or a few sites with fewer women; typically in Europe.¹²
Ongoing Publications	Extensive Peer-Reviewed Publications in Nature Medicine, Nature Health, and Radiology AI; dozens of peer-reviewed presentations at major conferences.¹³	Validation Mostly in less diverse cohorts; shown in smaller scopes.¹⁴
Value & Cost	$40 Add-On, Increasing Coverage Increasingly covered by insurance; No extra time or radiation-seamless care; additional targeted expert review.¹⁵	$40-100 Add-On Limited insurance coverage; more limited value; no additional expert review.¹⁶

EBCD™

Typical AI Solutions

Cancer Detection Improvement

+21% Overall

+21% real-world (23% in dense breasts); detects aggressive cancers equitably.³

+10-20% Overall

+10-20% primarily in European studies (e.g., 29% for Transpara replacing a second reader); 5-30% variable by product, with limited or nonsignificant evidence of cancer detection rate increases in real-world US studies.⁴

Equity & Inclusivity

Equitable Across All

No differences by race, ethnicity, or density; +20% in Black women; addresses disparities.⁵

Limited Equity Focus

Benefits for dense breasts noted; sparse data on race/ethnicity equity, particularly from the US.⁶

Core Approach

AI + Expert Review Workflow

Built-in specialist double-reading on all flagged cases.⁷

AI as Add-On Aid

Single-reader with AI assistance; no routine second review.⁸

Recall Reduction

17% Fewer Recalls

17% decrease in recall rate at one practice in 4 months through EBCD™, reducing patient anxiety and unnecessary tests.⁹

Mixed Results

Some reductions claimed; often neutral or increased recalls in studies.¹⁰

Real-World Evidence

579,583 Women Studied

Massive real-world data in 5 practices across the U.S. (200+ sites) shows additional cancers found nationally.¹¹

Smaller Studies

Studies on one or a few sites with fewer women; typically in Europe.¹²

Ongoing Publications

Extensive Peer-Reviewed

Publications in Nature Medicine, Nature Health, and Radiology AI; dozens of peer-reviewed presentations at major conferences.¹³

Validation

Mostly in less diverse cohorts; shown in smaller scopes.¹⁴

Value & Cost

$40 Add-On, Increasing Coverage

Increasingly covered by insurance; No extra time or radiation-seamless care; additional targeted expert review.¹⁵

$40-100 Add-On

Limited insurance coverage; more limited value; no additional expert review.¹⁶

1. Enhanced Breast Cancer Detection | AI Mammography. myebcdmammo.com. https://myebcdmammo.com/

2. Louis LD, Wakelin EA, McCabe M, Yang AY, Kim JG, Lee CI, Buist DSM, Sorensen AG, Haslam B. (in press). Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment. Nature Health.

Louis L, Haslam B, Kim J, Sorensen G. An AI-guided expert review process can lower radiologist recall rates. Paper presented at: Society of Breast Imaging Symposium; April 11-14, 2025; Montréal, Canada.

3. Louis LD, Wakelin EA, McCabe M, Yang AY, Kim JG, Lee CI, Buist DSM, Sorensen AG, Haslam B. (in press). Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment. Nature Health.

Haslam B, Kim J, Soresen AG. Abstract PO2-29-04: An AI-based safeguard process to reduce aggressive missed cancers in dense breasts at screening mammography. Cancer Research. 2024;84(9_Supplement):PO2-29. https://doi. org/10.1158/1538-7445.SABCS23-PO2-29-04.

Kim JG, Holt JS, Aujero M, Haslam B. An AI-driven safeguard review process helps detect aggressive breast cancers. Paper presented at: Radiological Society of North America Annual Meeting; December 1-5, 2024; Chicago, IL. https:// www.rsna.org/-/media/files/rsna/annual-meeting/future-and-past-meetings/rsna-2024-meeting-program.pdf (pg. 3006).

4. Hernström V, Josefsson V, Sartor H, Schmidt D, Larsson AM, Hofvind S, Andersson I, Rosso A, Hagberg O, Lång K. Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study. The Lancet Digital Health. 2025 Mar 1;7(3):e175-83. (29% increase in cancer detection when used as a second reader in place of a human reader)

Letter H, Peratikos M, Toledano A, Hoffmeister J, Nishikawa R, Conant E, Shisler J, Maimone S, Diaz de Villegas H. Use of artificial intelligence for digital breast tomosynthesis screening: a preliminary real-world experience. Journal of Breast Imaging. 2023 May 1;5(3):258-66. (No difference in cancer detection between US sites using iCAD vs. not using iCAD)

iCAD Science (23-27% increase in cancer detection rate reported by customers). icadmed.com. https://www.icadmed. com/about/science/

Hologic Genius AI Detection Technology (9% improvement in reader study). hologic.com. https://www.hologic.com/ hologic-products/breast-health-solutions/genius-ai-detection-technology.

iCAD and Densitas Partner to Enhance Precision Breast Health (8% improved sensitivity). densitashealth.com. April 16, 2024. https://densitashealth.com/news/icad-and-densitas-partner-to-enhance-precision-breast-health-with- leading-ai-solutions-for-mammography-quality-cancer-detection-and-risk-evaluation/.

5. Louis LD, Wakelin EA, McCabe M, Yang AY, Kim JG, Lee CI, Buist DSM, Sorensen AG, Haslam B. (in press). Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment. Nature Health.

6. Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations. Hologic Press Release. December 2, 2024. https://www.hologic.com/about/press-release/hologic- presents-new-research-demonstrating-how-its-breast-imaging-ai-solution. (Similar performance in 7,500 US DBT cases from different ethnicities)

Nguyen DL, Ren Y, Jones TM, Thomas SM, Lo JY, Grimm LJ. Patient characteristics impact performance of AI algorithm in interpreting negative screening digital breast tomosynthesis studies. Radiology. 2024 May 21;311(2):e232286. (Higher false positives in Black than White patients)

Oberije CJ, Currie R, Leaver A, Redman A, Teh W, Sharma N, Fox G, Glocker B, Khara G, Nash J, Ng AY. Assessing artificial intelligence in breast screening with stratified results on 306 839 mammograms across geographic regions, age, breast density and ethnicity: A Retrospective Investigation Evaluating Screening (ARIES) study. BMJ Health & Care Informatics. 2025 May 14;32(1):e101318. (Similar performance across age, density, and ethnic groups in 300,000+ cases in the UK)

7. Kim JG, Holt JS, Aujero M, Haslam B. An AI-driven safeguard review process helps detect aggressive breast cancers. Paper presented at: Radiological Society of North America Annual Meeting; December 1-5, 2024; Chicago, IL. https:// www.rsna.org/-/media/files/rsna/annual-meeting/future-and-past-meetings/rsna-2024-meeting-program.pdf (pg. 3006).

8. Hologic Genius AI Detection Technology (single-reader aid). hologic.com. https://www.hologic.com/hologic-products/ breast-health-solutions/genius-ai-detection-technology.

Transpara Breast AI (works in single or double reading). screenpoint-medical.com. https://screenpoint-medical.com/ evidence#evidenceworkflow.

Artificial Intelligence for Cancer Detection by iCAD (AI-powered aid). icadmed.com. https://www.icadmed.com/.

9. Louis L, Haslam B, Kim J, Sorensen G. An AI-guided expert review process can lower radiologist recall rates. Paper presented at: Society of Breast Imaging Symposium; April 11-14, 2025; Montréal, Canada. (17% drop in recall rate during a pilot study at one practice)

10. iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates [NH3]icadmed.com. February 28, 2024. https://www.icadmed.com/about/news-events/press-releases/ icad-highlights-promising-clinical-data-demonstrating-ability-to-reduce-breast-interval-cancer-rates-and- decrease-recall-rates-at-ecr-2024-showcases-additional-platform-offerings/.

Eisemann N, Bunk S, Mukama T, Baltus H, Elsner SA, Gomille T, Hecht G, Heywang-Köbrunner S, Rathmann R, Siegmann-Luz K, Töllner T. Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. Nature medicine. 2025 Mar;31(3):917-24. (2.35% non-significant decrease in recall rate using AI in Germany)

Artificial Intelligence for Digital Breast Tomosynthesis (7.2% reduction in recall rate when using Profound AI in a reader study). icadmed.com. https://www.icadmed.com/wp-content/uploads/2023/11/DMM253-Reader-Studies-Results-Rev-B.pdf

11. Louis LD, Wakelin EA, McCabe M, Yang AY, Kim JG, Lee CI, Buist DSM, Sorensen AG, Haslam B. (in press). Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment. Nature Health.

12. Hologic Groundbreaking New Data on AI-Powered Mammography (5,000 exams). hologic.com. https://www.hologic. com/about/press-release/hologic-presents-new-research-demonstrating-how-its-breast-imaging-ai-solution.

Conant EF, et al. Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis (smaller reader study). Radiol Artif Intell. 2019. https://doi.org/10.1148/ryai.2019180096.

Nepute JA, Peratikos M, Toledano AY, Salvas JP, Delks H, Shisler JL, Hoffmeister JW, Madden CM. Improved Breast Cancer Detection with Artificial Intelligence in a Real-World Digital Breast Tomosynthesis Screening Program. Clinical Breast Cancer. 2025 May 9.

Elías-Cabot E, Romero-Martín S, Raya-Povedano JL, Brehl AK, Álvarez-Benito M. Impact of real-life use of artificial intelligence as support for human reading in a population-based breast cancer screening program with mammography and tomosynthesis. European Radiology. 2024 Jun;34(6):3958-66.

Waugh J, Evans J, Miocevic M, Lockie D, Aminzadeh P, Lynch A, Bell RJ. Performance of artificial intelligence in 7533 consecutive prevalent screening mammograms from the BreastScreen Australia program. European Radiology. 2024 Jun;34(6):3947-57.

13. Lotter W, Diab AR, Haslam B, Kim JG, Grisot G, Wu E, Wu K, Onieva JO, Boyer Y, Boxerman JL, Wang M. Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach. Nature Medicine. 2021;27(2):244-9. https://doi.org/10.1038/s41591-020-01174-9.

Kim JG, Haslam B, Diab AR, Sakhare A, Grisot G, Lee H, Holt J, Lee CI, Lotter W, Sorensen AG. Impact of a categorical AI system for digital breast tomosynthesis on breast cancer interpretation by both general radiologists and breast imaging specialists. Radiology: Artificial Intelligence. 2024;6(2):e230137. https://doi.org/10.1148/ryai.230137.

Louis LD, Wakelin EA, McCabe M, Yang AY, Kim JG, Lee CI, Buist DSM, Sorensen AG, Haslam B. (in press). Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment. Nature Health.

14. ScreenPoint Transpara FDA clearance and trials. screenpoint-medical.com. https://screenpoint-medical.com/evidence.

Hologic Genius AI Detection Technology (FDA-cleared with trial data). hologic.com. https://www.hologic.com/hologic- products/breast-health-solutions/genius-ai-detection-technology.

Artificial Intelligence for Cancer Detection by iCAD (FDA-cleared, 51 clinical studies). icadmed.com. https://www. icadmed.com/about/science/.

Lunit Insight (FDA-cleared) https://www.lunit.io/en/publications?category=Breast

15. Enhanced Breast Cancer Detection | AI Mammography (convenience and cost details). myebcdmammo.com. https:// myebcdmammo.com/.

16. Mammogram+ (general enhancement, $50 add-on). simonmed.com. https://www.simonmed.com/services/ mammogram-plus.

SecondReadAI (general enhancement, $75 add-on) https://southtownsradiology.com/services/second-read-ai/

Susan G. Komen gives cost range as $40-$100 https://www.komen.org/blog/ai-assisted-mammogram